STA-21

STA-21

Application

STA-21 has been used as a signal transducer and activator of transcription 3 (STAT3) inhibitor to study its effects on glioblastoma and primary glioblastoma cells. It has also been used as a STAT3 dimerization inhibitor to study its effects on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) production in human lung cancer cell line.

Biochem/physiol Actions

STA-21 is a STAT3 inhibitor that reduces the constitutively high STAT3 transcriptional activity in Caov-3 and MDA-MB-435s cultures (by 9.125- and 5.765-fold, respectively, post 48-hr 20 µM treatment) by disrupting STAT3 homodimerization, an essential process for STAT3 nuclear localization and DNA-binding activity. STA-21 selectively inhibits the growth and survival of breast carcinoma cells with constitutive Stat3 signaling (26%, 25%, 56% apoptotic cells, respectively, in MDA-MB-231, MDA-MB-435s, and MDA-MB-468 cultures, respectively, post 48-hr 20 µM treatment) but not those without (﹤10% apoptosis in MCF7, MDA-MB-453, HSF cultures post 48-hr 20 µM treatmen). STA-21 is reported to alleviate autoimmune inflammation in a murine model of rheumatoid arthritis (RA; 0.5 mg/kg; 3X i.p./week) and reduce airway inflammation in allergic mice with psoriatic inflammation (20 µg/mouse/day topically) in vivo.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575898 STA-21 yellow to brown SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear powder ≥95% (HPLC)
£160.18 (exc VAT) per 1MG
-
+
3575899 STA-21 yellow to brown SIGMA-ALDRICH −20°C DMSO: 2 mg/mL, clear powder ≥95% (HPLC)
£491.68 (exc VAT) per 5MG
-
+